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Neonatal Hyperbilirubinemia in infants with G6PD
c.563C > T Variant
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Abstract
Background: There is a strong correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and
neonatal hyperbilirubinemia with a rare but potential threat of devastating acute bilirubin encephalopathy. G6PD
deficiency was observed in 4–14% of hospitalized icteric neonates in Pakistan. G6PD c.563C > T is the most
frequently reported variant in this population. The present study was aimed at evaluating the time to onset of
hyperbilirubinemia and the postnatal bilirubin trajectory in infants having G6PD c.563C > T.
Methods: This was a case–control study conducted at The Aga Khan University, Pakistan during the year 2008. We
studied 216 icteric male neonates who were re-admitted for phototherapy during the study period. No selection
was exercised. Medical records showed that 32 were G6PD deficient while 184 were G6PD normal. Each infant was
studied for birth weight, gestational age, age at the time of presentation, presence of cephalhematoma, sepsis and
neurological signs, peak bilirubin level, age at peak bilirubin level, days of hospitalization, whether phototherapy or
exchange blood transfusion was initiated, and the outcome. During hospital stay, each baby was tested for
complete blood count, reticulocyte count, ABO and Rh blood type, direct antiglobulin test and quantitative G6PD
estimation [by kinetic determination of G6PDH]. G6PDgenotype was analyzed in 32 deficient infants through
PCR-RFLP analysis and gene sequencing.
Results: G6PD variants c.563C > T and c.131 C > G were observed in 21 (65%) and three (9%) of the 32 G6PD
deficient infants, respectively. DNA of eight (25%) newborns remained uncharacterized. In contrast to G6PD normal
neonates, infants with c.563C > T variant had significantly lower enzyme activity (mean ± 1SD; 0.3 ± 0.2 U/gHb vs.
14.0 ± 4.5 U/gHb, p< 0.001) experienced higher peak levels of total serum bilirubin (mean ± 1SD; 16.8 ± 5.4 mg/dl
vs. 13.8 ± 4.6 mg/dl, p = 0.008) which peaked earlier after birth (mean ± 1SD 2.9 ± 1.6 vs. 4.3 ± 2.3 days, p = 0.007). No
statistically significant difference was observed in mean weight, age at presentation, hemoglobin, reticulocyte
count, TSH level, hospital stay or in the frequency of initiation of phototherapy or blood exchange between the
two groups.
Conclusions: We concluded that infants with G6PD c.563C > T variant developed jaundice earlier than infants with
normal G6PD enzyme levels. Compared to G6PD normal infants, G6PD c.563C > T carrying infants had significantly
low G6PD activity.
Background
G6PD deficiency is the most common red cell enzymo-
pathy estimated to affect 400 million people worldwide
[1]. A recent systematic review showed a global preva-
lence of 4.9% for G6PD deficiency [2]. There is signifi-
cant association of G6PD deficiency with neonatal
hyperbilirubinemia in the immediate perinatal period
[3]. Though rare, significant hyperbilirubinemia poses a
potential threat for permanent neurological deficit or
kernicterus. Studies indicate that insufficient hepatic me-
tabolism of unconjugated bilirubin [4] rather than
increased hemolysis [5] is the major contributor to neo-
natal hyperbilirubinemia. In addition, the UGT1A1 mu-
tation of promoter or coding region in G6PD
contributes to a Gilbert like condition [6,7] in G6PD de-
ficient infants. To date 400 biochemical G6PD variants
have been identified corresponding to 186 G6PD muta-
tions [8], with most being single point mutations. Recent
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advances in technology have permitted accurate molecu-
lar characterization in many regions of the globe. How-
ever, few reports (primarily from Chinese populations)
have investigated the relationship between G6PD var-
iants and the severity of neonatal hyperbilirubinemia
[9-11], while others focused only on identification of
G6PD variants in icteric infants [12-14].
Two large national Pakistani studies (n = 1624 and
6454 patients respectively) reported that 26% [15] and
30% [16] of all hospital admissions were required for
evaluation of neonatal jaundice. Low birth weight, ABO
or Rh incompatibility and sepsis were recognized as im-
portant contributors for jaundice [15] while G6PD defi-
ciency was observed in 8% of jaundiced infants [16].
With two thirds of infants in Pakistan being born out-
side hospitals, the true magnitude of neonatal hyperbilir-
ubinemia is expected to be much higher than observed
in these studies. Reported incidence of G6PD deficiency
in Pakistani males ranges from 2 to 4% [17-26] with a
higher incidence of 8% in Pathans. G6PD c.563C > T is
the most frequent variant [21,27]. National literature re-
view indicated a higher prevalence [4 to14%] of G6PD
deficiency in jaundiced neonates [16,28-33]. These
reports also showed that the infants developed jaundice
within their first five days of life and a substantial num-
ber of them required phototherapy and exchange blood
transfusions [34]. Unfortunately up to 22% suffered from
acute bilirubin encephalopathy and their mortality was
as high as 4% [16,30]. Despite extensive study of G6PD
deficiency in Pakistani neonates, there has been no na-
tional interest in molecular characterization of G6PD
gene. For example, we don’t know whether infants with
various G6PD variants behave differently.
G6PD c.563C > T is the most frequent variant in
Pakistan [21,27]. Because it is associated with very low
enzyme activity [1], we hypothesized that the neonates
inheriting this variant would exhibit severe hyperbiliru-
binemia requiring more aggressive management com-
pared to icteric infants having normal G6PD activity.
The present study was aimed at evaluating the time to
onset of hyperbilirubinemia and the postnatal bilirubin
trajectory in infants having G6PD c.563C > T.
Methods
Protocol for management of hyperbilirubinemia
Situated in Southern Pakistan, The Aga Khan University
is an academic tertiary care hospital with advanced neo-
natal care facilities. Over 600 neonates are admitted an-
nually to the neonatal intensive care unit (NICU) and
treated for various disorders including hyperbilirubine-
mia. Our institution follows the guidelines laid by
American Academy of Pediatrics for management of
neonatal hyperbilirubinemia [29]. Hyperbilirubinemia
was defined as a serum total bilirubin [STB] of >15 mg/
dl in the first week of life and infant’s age was measured
in hours and approximated to days. Infants were
assessed for jaundice every 8–12 h by our medical and
nursing staff. Indications for STB estimation included:
onset of jaundice in first 24 h, excessive jaundice for age
and deepening or unexplained jaundice [29]. Blood was
drawn at 48 h in all infants for mandatory bilirubin de-
termination. For designation of risk, hour-specific STB
was plotted on Bhutani’s nomogram [29]. Subsequent
blood draws were made daily between 6–8 am to avoid
systematic bias. More frequent STB estimations were
done for infants in moderate and higher risk zones.
Common causes of pathologic hyperbilirubinemia con-
sidered in each neonate included ABO or Rh incompat-
ibly, sepsis, hematomas, prematurity, hypothyroidism
[35]. ABO or Rh incompatibility was identified by a posi-
tive direct antiglobulin test in an infant born to a blood
group O or Rh negative mother. Sepsis was defined as
systemic inflammatory response syndrome associated
with suspected or proven infection. Criteria included: a
core temperature of > 38.5°C or < 36°C, a heart rate of >
180 or < 100/min, a respiratory rate of > 50/min, systolic
blood pressure of < 65 mmHg and white cell count of <
5 or >34 × 109/l [36]. Elevated C-reactive protein of >
10 mg/L was considered as a biochemical marker for in-
fection [37]. Additionally thrombocytopenia < 80 × 109/l
was observed as a marker of severe sepsis [36]. Pub-
lished normograms correlating age [in hours] and STB
were utilized for evaluating the need of phototherapy
or exchange transfusion [29].G6PD enzyme test was
performed for all babies who were re-admitted for
phototherapy. TSH assessment was done routinely as
an integral component of the neonatal screening pro-
gram irrespective of icterus. Infants were discharged
upon demonstrating resolution of clinical jaundice with
declining STB. Follow-up visits were scheduled for all
infants.
Subjects studied
Computerized hospital data indicated 455 neonates with
hyperbilirubinemia during January 1 to December 31, 2008.
There were 270 icteric neonates who were re-admitted in
NICU for phototherapy. After excluding female infants
[n=52], cases with missing data and incomplete informa-
tion [n=2], medical records were reviewed for 216 icteric
babies. All 216 babies were tested for G6PD enzyme
activity.
Clinical Details: The following details were extracted
from the medical record of all neonates: birth weight,
gestational age at birth, age at the time of presentation
of jaundice, presence of cephalhematoma, sepsis and
neurological signs, peak bilirubin level, age at peak bili-
rubin level, days of hospitalization, whether photother-
apy was initiated, and outcome.
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Laboratory parameters: During hospital stay, each baby
was tested for complete blood count [CoulterW Gen-S;
Coulter Electronics, Hialeah FL, USA], reticulocyte count
[CoulterW Gen-S; Coulter Electronics, Hialeah FL, USA],
ABO and Rh blood group [Classic DiaMed- ID, Cressier,
Switzerland], direct antiglobulin test [Classic DiaMed- ID,
Cressier, Switzerland], total direct and indirect bilirubin
levels [Synchron, Beckman, CoulterW, USA] and serum
TSH [E170, RocheW, Germany]. G6PD quantitative en-
zyme assay [TrinityW, Biotech kit No 345, Wicklow,
Ireland] was normalized using the patient’s hemoglobin
according to manufacturer’s instructions. The test
involved kinetic determination of G6PDH in blood at
340 nm. The neonatal reference interval for G6PD has
been previously established in our laboratory, and ranges
from 7 to19 U/gHb; G6PD deficiency was diagnosed when
an enzyme level was < 7 U/gHb.
Molecular analysis
The blood samples sent for G6PD enzyme assay were
saved for molecular analysis if quantitative enzyme defi-
ciency was observed. DNA was extracted from white
cells using QuigenW kit and a three steps strategy was
used to characterize G6PD at molecular level. All sam-
ples were scanned for c.563C > T mutation and c.1311C
> T polymorphism by restriction fragment length poly-
morphism (PCR-RFLP). Failure to detect c.563C > T
prompted for a more detailed PCR analysis for nine
common mutations prevalent in South Asia: c.95A > G,
c.1311C > T, c.392 G > T, c.871 G > A, c.1003 A > G,
c.1024 C > T, c.1376 G > C, c.1376 G > T and c.1388 G
> A[21,38-41]. When a sample remained uncharacter-
ized after these first two steps, more comprehensive gen-
etic analysis with amplification of 9–12 exons [42] was
performed followed by sequence analysis (MacrogenW,
Soule, Korea). G6PD genotype of non-deficient infants
was not analyzed. G6PD c.563C > T is associated with
very low levels of enzyme activity which is usually <
1 U/gHb [43]. Therefore it was assumed that this variant
would not be present in G6PD normal infants.
Statistical analysis
All the data was entered into SPSS version 16 [SPSS
Inc., Chicago, IL, USA] for analysis. Continuous as well
as discrete data were compared for G6PD normal, defi-
cient and G6PD c.563C > T variant utilizing Student’s T
test if the distribution was normal. The threshold of sig-
nificance was considered as a p < 0.05.
Ethical concerns
The study was approved by institutional ethical review
committee of The Aga Khan University Hospital [ERC
approval No.# Pat 506/ERC 06]. Informed consent was
taken from the parents and the data was entered after
recoding to maintain anonymity. Parents were informed
of the possibility of mutation remaining unidentified.
Results
Demographics
We studied 216 icteric male infants who were re-
admitted for phototherapy. G6PD deficiency was
observed in 32 babies [15%] with a low G6PD enzyme
activity of 0.6 ± 0.9 U/gHb. There were 184 infants who
had normal G6PD levels with a mean ± 1SD of
14.0 ± 4.5 U/gHb. The variables of 184 G6PD normal
and 32 G6PD deficient male infants are summarized in
Table 1. G6PD deficient infants developed icterus earlier
than G6PD normal infants (Mean ± 1SD; 1.6 ± 1.3 vs.
2.2 ± 2.2 days, p = 0.026).
Molecular analysis and G6PD assay
Thirty two G6PD deficient infants were tested for G6PD
variants. G6PD c.563C > T and c.131C > G variants were
detected in 21 (65%) and three (9%) infants respectively;
the genotype of eight (25%) infants remained uncharac-
terized. The later include three samples that could not
be fully analyzed because of insufficient DNA and five
samples where the genetic variants were not ascertained
at the completion of our full workup. Associated
c.1311 T polymorphism was seen in four samples (19%)
with c.563C > T variant. Infants with G6PD c.563C > T
mutation showed markedly low levels of G6PD enzyme
activity (mean ± 1SD; 0.3 ± 0.2 U/gHb) in comparison
with G6PD normal infants (mean ± 1SD; 14.0 ± 4.5,
p < 0.001). G6PD genotype of G6PD normal infants was
not determined.
Clinical and laboratory evaluation and outcome
G6PD normal (n = 184) and deficient groups (n = 32)
showed statistically significant differences for: age at
manifestation of jaundice, peak bilirubin level and age at
peak bilirubin, hemoglobin and reticulocyte count
(Table 1). In contrast to G6PD normal infants, G6PD de-
ficient infants depicted clinical jaundice earlier (mean ±
1SD; 1.6 ± 1.3 days vs. 2.2 ± 2.1 days, p = 0.026), reached
higher peak bilirubin levels (mean ±1SD; 16.7 ± 6.0 mg/
dl vs. 13.8 ± 4.6 mg/dl, p = 0.002) at an earlier age (mean
± 1SD; 2.6 ± 1.9 days vs. 4.3 ± 2.3 days, p < 0.001). The
results showed that G6PD deficient neonates presented
earlier consistent with the onset of overt clinical jaun-
dice as the trigger for hospital admission. G6PD normal
infants took a mean of 2.2 ± 2.2 days to develop peak
jaundice from its onset in contrast to 1.6 ± 1.3 days taken
by G6PD deficient infants (p-value 0.026). Hemoglobin
(mean ± 1SD; 16.5 ± 2.5 vs. 15.5 ± 1.9 g/dl, p-value 0.036)
and reticulocyte count (mean ± 1SD; 4.0 ± 2.2 vs.
5.0 ± 2.5, p-value 0.047) showed significant differences in
the two groups. However, no statistically significant
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difference was seen in mean bodyweight, TSH levels,
length of hospital stay and frequency of need to initiate
phototherapy or blood exchange. Comparison of G6PD
c.563 > T group (n = 21) with G6PD normal infants
(n = 184) showed that these G6PD variant infants were
at higher risk for early and moderate hyperbilirubinemia
(Table 1). Exchange transfusion was needed in 15% of
G6PD normal and 12% in G6PD deficient infants.
Figure 1 showed that infants carrying c.563C > T mu-
tation achieved peak bilirubin within five days of their
life [except one baby] in contrast to normal infants
who demonstrated peak levels dispersed between days
1–17 of their life. It was observed (Figure 2) that the
initial estimated serum total bilirubin levels were sig-
nificantly higher for infants inheriting G6PD c.563C >
T when compared to G6PD normal infants during
their first 72 h of life [0–3 days] of life (p-value 0.010,
< 0.001 and 0.002 respectively).
There were 96 G6PD normal (57%) and nine G6PD
c.563C > T infants (56%) who were anemic for age and
additionally 33 (37%) and 3 (33%) of them respectively
showed reticulocytosis. Although there were statistically
significant differences in hemoglobin, haematocrit and
reticulocyte count of two groups; the reported values
largely represent a normal range during this immediate
postnatal time frame.
The possible etiologic risk factors for hyperbilirubinemia
in the G6PD normal icteric infants are listed in Table 2.
Collectively, prematurity (gestational period 35 – 36 weeks)
with associated sepsis constituted the most frequent patho-
logical reason for icterus, accounting for 21% of all the
causes. Mean [±SD] G6PD enzyme activity in this group
(n=39) was 13.8±3.8 U/gHb but G6PD genotype was not
determined in any infant. The etiology remained unresolved
in a significant number of infants (n=77 or 42%). These
infants had normal G6PD enzyme levels [mean 14.4± 6.1U/
gHb] but as stated before none of them was tested for
G6PD variant. Additional risk factors for hyperbilirubine-
mia were observed in eight or 23% G6PD deficient infants;
including pre-term (n=4), ABO or Rh incompatibility
(n=3), and preterm with sepsis (n=1). However, no statisti-
cally significant difference was observed when the two
G6PD deficient groups [with and without confounders]
were compared for age at peak bilirubin and peak bilirubin
achieved [p=0.590 and p=0.873]. Similar confounders
were present in three neonates with G6PD c.563C > T vari-
ant (pre-term n=1, preterm and sepsis n=1 and ABO in-
compatibility n=1). However, statistical significance in peak
bilirubin levels and age at peak bilirubin levels between
G6PD c.563C > Tand G6PD normal infant wasmaintained
after exclusion of these three neonates.
Complete recovery was observed in all infants (n= 216).
Discussion
We characterized G6PD genes in 32 neonates and iden-
tified G6PD c.563C > T as the most frequent variant
while c.131 C > G was less common. We studied a small
population of G6PD deficiency infants but nevertheless
G6PD c.563C > T was observed as an important risk
factor for early development and moderately severe
hyperbilirubinemia in neonates. Moreover, G6PD c.563C
> T variant was also implicated in driving earlier and
higher peak bilirubin levels compared to G6PD normal
newborns. Additionally, at the time of recognition of
Table 1 Clinical and laboratory parameters of jaundiced males infants with (n =32) and without G6PD deficiency
(n =184). G6PD variants were analyzed for G6PD deficient infants only (n =32)
Variables G6PD normal G6PD deficient G6PD Variants P-value
c.563C > T c.131C > G Unknown
n 184 32 21 3 8
Weight (kg) 2.7 ± 0.7 2.9 ± 0.6 2.9 ± 0.5 2.6 ± 0.8 2.8 ± 1.0 0.157
Age at presentation (days) 2.2 ± 2.2 1.6 ± 1.3* 1.6 ± 1.4 1.6 ± 0.6 1.5 ± 1.1 0.215
Icterus in first 24 h of life n (%) 63(33.7) 15(46.9) 10(47.6) 1(33) 4(50) <0.001**
Hemoglobin (g/dl) 16.5 ± 2.5 15.5 ± 1.9* 15.7 ± 2.09 13.9 ± 0.32 15.7 ± 1.8 0.172
Retic count (%) 4.0 ± 2.2 5.0 ± 2.5* 4.9 ± 2.5 5.1 ± 0.8 5.0 ± 3.2 0.140
G6PD activity (U/gHb) 14.0 ± 4.5 0.6 ± 0.9* 0.3 ± 0.2 2.2 ± 2.2 1.6 ± 2.3 <0.001**
TSH (μIU/ml) 5.9 ± 4.7 6.9 ± 4.5 7.0 ± 4.3 12.2 ± 9.2 5.1 ± 3.2 0.355
Peak bilirubin (mg/dl) 13.8 ± 4.6 16.7 ± 6.0* 16.8 ± 5.4 14.9 ± 1.2 17.2 ± 8.8 0.008**
Age at peak bilirubin (days) 4.3 ± 2.3 2.6 ± 1.9* 2.9 ± 1.6 1.6 ± 1.5 2.6 ± 2.7 0.007**
Frequency of Phototherapy (n/%) 154/82 29/90 18/86 3/100 8/100 0.701
Frequency of blood exchange (n/%) 28/15 4/12 3/14 0/0 1/13 0.934
Hospital stay (days) 6.2 ± 4.1 5.6 ± 3.1 5.2 ± 3.1 4.6 ± 1.5 7.1 ± 3.5 0.254
All values are expressed as mean ± 1SD.
*p< 0.05 between G6PD normal and deficient neonates** P-value< 0.05 between G6PD c.563C > T variant group and G6PD normal infants.
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hyperbilirubinemia, the serum total bilirubin was signifi-
cantly higher for this variant in contrast to G6PD nor-
mal infants of the same age group.
G6PD Mediterrenean or G6PD c.563C > T variant
(188 Ser ! Phe) is a type II mutation and is situated in
exon 6 of G6PD gene. Its high occurrence in neonates is
no surprise as it has been previously reported from Paki-
stani population [21,27]. Its association with very low
G6PD enzyme activity is well known and our study con-
firmed that. A literature review indicated a paucity of
data regarding association of G6PD c.563C > T with the
clinical course of neonatal hyperbilirubinemia. Ainoon
and his colleagues studied 17 male infants with neonatal
hyperbilirubinemia secondary to G6PD c.563C > T vari-
ant. They observed icterus in 8 infants within first 48 h
of their life, with a mean peak bilirubin levels [231.8
umol/l or 13.4 mg/dl] at mean age of 3.8 days; 14% of
these neonates required photo therapy [44]. However, they
did not have a comparable control group of G6PD normal
infants. Few individual reports described the prevalence of
G6PD c.563C > T variant in neonates. For example, it was
seen in 3 of 70 (4%) icteric Egyptian infants [12], 12 of 65
(18%) G6PD deficient Saudi infants [14] and 39 of 43
(91%) G6PD deficient Sardinian neonates [13]. All these
reports lack clinical description. A few reports from Chin-
ese population illustrated G6PD variants in neonatal
hyperbilirubinemia but those reports did not demonstrate
G6PD c.563C > T and therefore their results were not
comparable to our work [11,45]. Kaplan in 2001 studied
52 infants with G6PD c.563C > T and observed hyperbilir-
ubinemia in 16 (30.8%) neonates, in contrast to 10 (6%)
controls [3]. The first STB value (done at 3 h) in 13 of 28
neonates was greater than or equal to mean and such
infants were more likely to develop hyperbilirubinemia
compared to 3 of 24 with a first STB less than the mean
(relative risk 3.7). There was statistically significant differ-
ence in the rise of mean bilirubin level between cases and
controls (0.15 mg/dl/h. vs. 0.13 mg/dl/h., p = 0.01).
Our study indicated statistically significant differences
in hemoglobin and reticulocyte counts in G6PD defi-
cient compared to normal infants, the reported values
for both groups largely remained within the normal
range for age-matched newborns. This finding is consist-
ent with published literature related to G6PD deficiency
and neonatal hyperbilirubinemia, where anemia and reti-
culocytosis are typically not evident [5].
G6PD c.131 C > G or Orissa variant (44 Ala!Gly) is
a type III G6PD variant with mutation localized in exon
Figure 1 Time to peak bilirubin in G6PD c.563C > T (closed circles) and G6PD normal (open circles) infants.
Moiz et al. BMC Pediatrics 2012, 12:126 Page 5 of 8
http://www.biomedcentral.com/1471-2431/12/126
3 of G6PD gene. There is a single report of G6PD Orissa
in one Malaysian neonate which was unassociated with
icterus [44]. In contrast, three icteric neonates presented
with G6PD Orissa in our study and each required photo-
therapy. This was unexpected as besides prematurity in
one infant, no associated confounder was identified.
Several risk factors were identified in G6PD normal
infants. The main risk factor for jaundice was identified
as prematurity either with or without sepsis in G6PD
normal infants. This finding corroborates previously
published reports describing a high risk of bilirubin
production-conjugation imbalance in borderline prema-
ture infants [46]. Sepsis which is a leading cause of neo-
natal mortality in developing countries [47] carries a
high risk for jaundice in preterm infants in contrast to
term infants [48]. Etiology of jaundice was unidentified
in 42% of our G6PD normal infants and the possibility
of G6PD variants could not be entirely excluded, as ana-
lysis for subtle G6PD variants was not made in G6PD
normal infants. Confounders were observed in 23%
G6PD deficient infants, including sepsis, prematurity
and Rh incompatibility. However, there was no statistical
difference in the peak bilirubin levels and age at peak
bilirubin level in the G6PD deficient groups with or
without confounders (p = 0.873 and 0.590 respectively).
This suggests a lack of significant contribution of con-
founders towards hyperbilirubinemia in G6PD deficient
infants. The absence of significant difference in the fre-
quency of exchange transfusion in G6PD normal and defi-
cient infants might be attributed to small sample size of
G6PD deficient group. In addition, G6PD normal infants
requiring exchange transfusion (n= 28) had comorbid like
septicemia and prematurity (25/28 or 89%) which would
have contributed towards significant hyperbilirubinemia
and hence a need for exchange transfusion.
Strengths and limitations
This study underscores the correlation of G6PD c.563C
> T with neonatal hyperbilirubinemia. Few limitations
were the small sample size of infants with G6PD defi-
ciency and absence of G6PD variants analysis in G6PD
normal infants. This approach likely underestimated the
contribution of G6PD deficiency in the genesis of hyper-
bilirubinemia as G6PD deficiency could certainly be co-
expressed in the background of other triggers, such as
mild prematurity or sepsis. The study was done in
Figure 2 Initial serum total bilirubin (STB) in G6PD normal (green bars) and G6PD c.563C > T group (red bar) as estimated during first
five days of life.
Table 2 Possible etiology of hyperbilirubinemia in 184
G6PD normal male neonates
Causes Possible etiology n (%)
Isolated Sepsis 32(17.3)
Gestation period 35–36 weeks 26(14.1)
ABO or Rh compatibility 8(4.3)
Cephalhematoma 2(1.0)
Inborn error of metabolism 1(0.5)
More than
one cause
Gestation period 35–36
weeks and sepsis
39(21.1)
Gestation period 35–36 weeks,
sepsis, ABO incompatibility
1(0.5)
Cephalhematoma and sepsis 1(0.5)
Unknown 77(41.8)
Total 184(100)
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hospitalized infants in whom timely initiation of appro-
priate management was performed. In Pakistan, 65% of
births occur at home and a selection bias may be at play
obscuring the true picture of the extent of problem.
Conclusions
We concluded that G6PD c.563C > T mutation carried a
risk of early development of moderate hyperbilirubinemia
in neonates. A large prospective and community based
study is required to elucidate the true burden of G6PD
c.563C > T and its association with neonatal icterus.
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